{"id":6003,"date":"2023-08-30T16:00:00","date_gmt":"2023-08-30T16:00:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/stuart-mcconchie-appointed-adjunct-board-member-to-realheart\/"},"modified":"2023-08-30T16:00:00","modified_gmt":"2023-08-30T16:00:00","slug":"stuart-mcconchie-appointed-adjunct-board-member-to-realheart","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/stuart-mcconchie-appointed-adjunct-board-member-to-realheart\/","title":{"rendered":"Stuart McConchie Appointed Adjunct Board Member to Realheart"},"content":{"rendered":"
Press release 2023-08-30<\/p>\n

Scandinavian Real Heart AB has decided to adjunct Stuart McConchie to the board of directors, after the nomination committee informed that it intends to propose him as new board member at the next general meeting. Stuart McConchie has held top positions at global medical technology companies for 25 years, guiding companies from research phase to commercialization of products.<\/strong><\/div>\n

McConchie has worked with several mechanical circulatory assist device companies, most recently as CEO of UK based Calon Cardio Technology, and previously U.S. Jarvik Heart and Australian HeartWare Inc, where he gained public company experience before the company\u2019s acquisition by Medtronic. Moreover, Stuart McConchie has extensive experience of clinical evaluation and regulatory affairs, including FDA interaction with numerous cardiac products.<\/span><\/span><\/span><\/span><\/p>\n

– We are excited to welcome Stuart McConchie to the board of directors. His strong track record from successfully guiding MedTech companies from research stage through approval and commercialization, especially with his strong experience in regulatory matters will be very valuable to Realheart in the period ahead, says Chairman of the Board Christer Norstr\u00f6m.<\/span><\/span><\/span><\/span><\/p>\n

\u201cInevitably the spectrum of mechanical cardiac assist will include effective four chamber support.
\nThe RealHeart<\/span><\/span><\/span>\u00ae<\/span><\/span>\u00a0<\/span><\/span><\/em>TAH is likely to be that device, and I am delighted to join the Realheart team\u201d.
\n– says Stuart McConchie<\/span><\/span><\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart<\/em><\/span><\/span>\u00ae<\/span><\/span><\/span><\/em> TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation.\u00a0<\/em><\/span><\/span>A unique concept in the medical technology world.<\/span><\/span><\/span><\/em><\/p>\n<\/div>\n